dr. mcdermott on the use of anti–pd-1 combinations in mrcc
Published 4 years ago • 92 plays • Length 1:24Download video MP4
Download video MP3
Similar videos
-
2:07
dr. mcdermott on tki/immunotherapy combinations in rcc
-
1:16
dr. mcdermott on toxicities of immunotherapy combinations in rcc
-
1:02
dr. mcdermott on novel immunotherapy combinations in rcc
-
1:15
dr. mcdermott on single-agent versus combination immunotherapy in rcc
-
0:42
dr. mcdermott on targeting pd-1 and pd-l1 in kidney cancer
-
3:10
immunology wars: monoclonal antibodies
-
57:18
webinar - pd-1/pd-l1 inhibitors: the first wave of immuno-oncology
-
1:25:29
the era of immuno-oncology in tnbc: implications for breast surgeons
-
1:27
dr. mcdermott on vegf/pd-1 inhibition in rcc
-
4:10
combination of medi0680, an anti-pd-1 antibody, with durvalumab, an anti-pd-l1 antibody
-
1:42
dr. mcdermott on immotion150 trial in rcc
-
0:54
dr. mcdermott on immunotherapy as a standard of care in rcc
-
1:33
dr. mcdermott on single-agent nivolumab in rcc
-
1:10
dr. mcdermott on the promise of pembrolizumab in non-clear cell rcc
-
1:38
dr. mcdermott on an analysis of the checkmate-214 study in rcc
-
1:22
dr. mcdermott on major findings of efficacy and safety of nivolumab in rcc
-
3:12
opdivo (nivolumab) the immunotherapy cancer treatment
-
1:53
dr. mcdermott on long-term benefit with nivolumab in rcc
-
1:09
dr. david f. mcdermott on nivolumab in rcc
-
1:23
dr. mcdermott discusses the future of immune checkpoints in rcc
-
2:07
immune checkpoint inhibitors, the next generation cancer therapy - creative biolabs
-
1:51
dr. mcdermott on vegf plus pd-1 in renal cell carcinoma